Announced substantial progress with lead program, INO-3107, as potential treatment for Recurrent Respiratory Papillomatosis (RRP) Positive data announced from Phase 1/2 trial Orphan Drug Designation granted by European Union Breakthrough Therapy
Announced substantial progress with lead program, INO-3107, as potential treatment for Recurrent Respiratory Papillomatosis (RRP) Positive data announced from Phase 1/2 trial Orphan Drug Designation granted by European Union Breakthrough Therapy
Inovio estimates its cash runway to extend into the second quarter of 2025. This projection includes an operational net cash burn estimate of approximately $26M for the first quarter of
Reports Q4 revenue $103,000, consensus $340,000. INOVIO’s President and Chief Executive Officer, Dr. Jacqueline Shea, said, “The past year has been transformative as we’ve reshaped INOVIO into a company that
Pre-earnings options volume in Inovio is 4.4x normal with calls leading puts 8:5. Implied volatility suggests the market is anticipating a move near 15.7%, or $1.57, after results are released.
Today, several major companies are expected to report earnings: Abercrombie Fitch (ANF), Campbell Soup (CPB), Foot Locker (FL), Infinera (INFN), Inovio Pharmaceuticals (INO), Thor Industries (THO), YPF Sociedad Anonima (YPF),